Global Hereditary Angioedema Therapeutics Market 2018-2022: Market to Grow at a CAGR of 8.94% with BioCryst ...

DUBLIN, Sept. 25, 2018 /PRNewswire/ --The "Global Hereditary Angioedema Therapeutics Market 2018-2022" report has been added to ResearchAndMarkets.com's offering. The Global Hereditary Angioedema Therapeutics Market to grow at a CAGR of 8.94% during the period 2018-2022.The report covers the present scenario and the growth prospects of the hereditary angioedema therapeutics market. To calculate the market size, the report considers the revenue generated from the hereditary angioedema therapeutics. The report also includes a discussion of the key vendors operating in this market. According to the report, one driver influencing this market is the increasing prevalence of hereditary angioedema. The rising cases of hereditary angioedema are increasing the possibility of transmission of the disease in the future generation. Therefore, it is expected that the distribution of the disease and the demand for the therapeutics will increase during the coming years, which in turn, results in the growth of the global hereditary angioedema therapeutics market.Development of monoclonal antibody is one of the major trends in the market. The development of therapeutics for the treatment of disease requires various approvals and experimentation. Shire after conducting clinical trials for the treatment of hereditary angioedema, launched the first monoclonal antibody, Lanadelumab (SHP643)Further, the report states that one challenge affecting this market is the high cost of treatment. Although the medications for HAE is covered under patient healthcare schemes in most countries, the indirect costs associated with the treatment makes the treatment quite expensive for the patients, leading to less patient adherence.Key vendorsBioCryst Pharmaceuticals Cipla CSL Pharming Group ShireKey Topics Covered:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPEPART 05: MARKET SIZING 2017-2022PART 06: FIVE FORCES ANALYSISPART 07: PIPELINE LANDSCAPEPART 08: MARKET SEGMENTATION BY PRODUCTSegmentation by product Comparison by product C1 inhibitors Icatibant Ecallantide Others - Market size and forecast 2017-2022 Market opportunity by productPART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE

Geographical segmentation Regional comparison Market opportunityPART 11: DECISION FRAMEWORKPART 12: DRIVERS AND CHALLENGESPART 13: MARKET TRENDSInnovative treatment strategies Improved route of administration products Development of monoclonal antibodyPART 14: VENDOR LANDSCAPELandscape disruptionPART 15: VENDOR ANALYSISVendors covered Vendor classification Market positioning of vendorsFor more information about this report visit https://www.researchandmarkets.com/research/pr68t5/global_hereditary?w=5Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.Media Contact:Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:https://www.prnewswire.com/news-releases/global-hereditary-angioedema-therapeutics-market-2018-2022-market-to-grow-at-a-cagr-of-8-94-with-biocryst-pharmaceuticals-cipla-csl-pharming-group--shire-dominating-300718693.htmlSOURCE Research and Markets

Let's block ads! (Why?)

https://markets.businessinsider.com/news/stocks/global-hereditary-angioedema-therapeutics-market-2018-2022-market-to-grow-at-a-cagr-of-8-94-with-biocryst-pharmaceuticals-cipla-csl-pharming-group-shire-dominating-1027564314

Bagikan Berita Ini